rEVO Biologics Company Profile

18:11 EDT 31st October 2014 | BioPortfolio

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company’s lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.


News Articles [431 Associated News Articles listed on BioPortfolio]

LFB’s rEVO Biologics attempts IPO

Recombinant protein therapeutics developer rEVO Biologics Inc. filed for its initial public offering.

rEVO files for IPO

rEVO Biologics Inc., a subsidiary of LFB S.A. (Les Ulis, France), filed to raise up to $74.8 million in an IPO on NASDAQ underwritten by Piper Jaffray; Guggenheim Securities; Roth Capital Partners; an...

rEVO biologics enrolls first patient in ATryn Phase III trial for preeclampsia

LFB Biotechnologies’ subsidiary rEVO Biologics has enrolled the first patient in its Phase III clinical trial of ATryn to treat preeclampsia.

rEVO Biologics proposes IPO

rEVO Biologics amends IPO

rEVO sets IPO terms

rEVO Biologics Inc., a subsidiary of LFB S.A. (Les Ulis, France), set the terms for its IPO on NASDAQ. It plans to sell 3.6 million shares at $13-$15. LFB plans to purchase $10 million of the IPO shar...

How is the post monoclonal antibodies (mAb) world going to develop in the future of biologics?

  As the pharma industry moves into the future of biologics production what challenges will they be facing? The field of biologics is currently on the brink of a new era of high tech drugs. These new...

A biologic by any other name would smell as sweet?

How important is a name?  In the case of biologics and biosimilars, billions of dollars depends on whether biosimilars can share the same name as branded biologics.  WonkBlog explains the biologic ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [82 Associated PubMed Articles listed on BioPortfolio]

When biologics should be used in systemic lupus erythematosus?

Recently, the use and evaluation of biologics increased in systemic lupus erythematosus (SLE). However, no international recommendation is available concerning the use of biologics with regards to the...

Demystifying the u.s. Food and drug administration: I. Understanding agency structure and function.

The U.S. Food and Drug Administration is the government agency responsible for oversight of the safety and efficacy of pharmaceuticals and devices, including biologics and devices that combine biologi...

Patch Test Results in Psoriasis Patients on Biologics.

The objective of this study was to determine the prevalence of positive patch tests in patients with psoriasis receiving biologics and whether these results differ from those of patients with psoriasi...

Assessment of the metabolism of therapeutic proteins and antibodies.

Introduction: In the last decade, our increased knowledge of factors governing the pharmacokinetics and metabolism of biologics (recombinant therapeutic proteins) has driven, and will continue to supp...

How Should We Evaluate Outcomes for Use of Biologics in the Knee?

In recent years, the use of biologics for the primary treatment and augmentation of treatment in patients with knee pathology has increased substantially. Techniques and applications for biologic prep...

Clinical Trials [25 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs) ...

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Biologics are routinely used for the treatment of rheumatoid arthritis (RA). Adalimumab is a human monoclonal antibody that inhibit the Tumor Necrosis Factor alpha (TNF-alpha). Identificat...

Companies [193 Associated Companies listed on BioPortfolio]

rEVO Biologics

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recom...

rEVO Biologics Inc.

rEVO Biologics Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address ...

rEVO Biologics, Inc.

rEVO Biologics, Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address ...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

Precision Biologics, Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic ...

More Information about "rEVO Biologics" on BioPortfolio

We have published hundreds of rEVO Biologics news stories on BioPortfolio along with dozens of rEVO Biologics Clinical Trials and PubMed Articles about rEVO Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of rEVO Biologics Companies in our database. You can also find out about relevant rEVO Biologics Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Blood
Latest News Clinical Trials Research Drugs Reports Corporate
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record